![Ian R. Ferrier](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ian R. Ferrier
Algemeen Directeur bij Bogart Delafield Ferrier LLC
Profiel
Ian R.
Ferrier is a professional with a current job as President & Chief Executive Officer at Bogart Delafield Ferrier LLC since 1982.
Dr. Ferrier has an undergraduate and graduate degree from The University of Edinburgh.
Actieve functies van Ian R. Ferrier
Bedrijven | Functie | Begin |
---|---|---|
Bogart Delafield Ferrier LLC | Algemeen Directeur | 01-01-1982 |
Eerdere bekende functies van Ian R. Ferrier
Bedrijven | Functie | Einde |
---|---|---|
Exponential Biotherapies, Inc.
![]() Exponential Biotherapies, Inc. Pharmaceuticals: MajorHealth Technology Exponential Biotherapies, Inc. discovers and develops drugs. It provides small molecule drugs to treat an inflammatory disorders, such as acute kidney injury, septic shock, radiation sickness, and avian influenza infections. The company was founded on July 31, 1996 and is headquartered in New York, NY. | Directeur/Bestuurslid | - |
Naurex, Inc.
![]() Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Directeur/Bestuurslid | - |
MDRNA, Inc.
![]() MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Directeur/Bestuurslid | - |
Opleiding van Ian R. Ferrier
The University of Edinburgh | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 4 |
---|---|
MDRNA, Inc.
![]() MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | Commercial Services |
Bogart Delafield Ferrier LLC | |
Exponential Biotherapies, Inc.
![]() Exponential Biotherapies, Inc. Pharmaceuticals: MajorHealth Technology Exponential Biotherapies, Inc. discovers and develops drugs. It provides small molecule drugs to treat an inflammatory disorders, such as acute kidney injury, septic shock, radiation sickness, and avian influenza infections. The company was founded on July 31, 1996 and is headquartered in New York, NY. | Health Technology |
Naurex, Inc.
![]() Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Health Technology |